Eledon pharmaceuticals receives fda clearance of ind application to evaluate tegoprubart for the prevention of rejection in kidney transplant recipients

Irvine, calif., aug. 01, 2022 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that the u.s. food and drug administration (fda) has cleared the company's investigational new drug (ind) application to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant.
ELDN Ratings Summary
ELDN Quant Ranking